

## ORIGINAL ARTICLE

### Early-onset sepsis in Malaysian neonatal intensive care units

Nem Yun BOO<sup>1\*</sup>, Eric Boon-Kuang ANG<sup>2</sup>, Siew Hong NEOH<sup>3</sup>, Ee Lee ANG<sup>4</sup>, Seok Chiong CHEE<sup>5</sup>, on behalf of the Malaysian National Neonatal Registry

<sup>1</sup>Department of Population Medicine, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Bandar Sungai Long, Selangor, Malaysia; <sup>2</sup> Department of Paediatrics, Sultanah Bahiyah Hospital, Ministry of Health, Alor Setar, Kedah, Malaysia; <sup>3</sup>Department of Paediatrics, Tunku Azizah Hospital, Ministry of Health, Kuala Lumpur, Malaysia; <sup>4</sup>Department of Paediatrics, Tengku Ampuan Rahimah Hospital, Ministry of Health, Klang, Selangor, Malaysia; <sup>5</sup>Department of Paediatrics, Selayang Hospital, Ministry of Health, Batu Caves, Selangor, Malaysia.

#### Abstract

**Objectives:** To determine the incidence, causative pathogens, morbidities, mortality, and risk factors associated with blood culture-positive early-onset sepsis (EOS,  $\leq 72$  hours of age) in symptomatic neonates admitted to the neonatal intensive care units (NICUs) of a middle-income country. **Study Design:** Retrospective cohort study using data submitted prospectively to the Malaysian National Neonatal Registry (MNNR). **Setting:** 44 Malaysian NICUs. **Participants:** All neonates born in 2015–2020. **Results:** EOS was reported in 991 neonates. The annual incidence of EOS increased from 0.46 to 0.49/1000 livebirths over the six years. The most common pathogen was *Streptococcus agalactiae* or Group B haemolytic streptococcus (GBS) (n=388, 39.2%), followed by *Escherichia coli* (*E. coli*) (n=80, 8.1%), *Klebsiella* spp (n=73, 7.4%), coagulase negative staphylococcus (CONS) (n=73, 7.4%), *Pseudomonas* spp (n=44, 4.4%) and methicillin-sensitive *Staphylococcus aureus* (n=34, 3.4%). The incidence of EOS due to GBS increased from 0.17 to 0.22/1000 livebirths. Morbidities and mortality were higher in those with EOS than without EOS. Multiple logistic regression analysis showed that Indian ethnic group, chorioamnionitis, gestation  $\geq 37$  weeks, female, spontaneous vaginal delivery, instrumental delivery, and surfactant therapy were significantly associated with increased risk of EOS due to GBS. Four factors were significantly associated with increased risk of non-GBS EOS (outborns, birthweight  $< 1000$  g, vaginal delivery, and surfactant therapy). Early continuous positive airway pressure was associated with significantly lower risk of EOS. **Conclusion:** The incidence of EOS showed an increasing trend in Malaysian NICUs. GBS was the most common causative pathogen. Several modifiable risk factors associated with EOS have been identified.

**Keywords:** Early-onset sepsis, neonatal intensive care units, Malaysia, group B haemolytic streptococci, early CPAP, surfactant therapy

#### INTRODUCTION

Early-onset sepsis (EOS), defined as blood culture-positive infection in symptomatic neonates within the first 72 hours of life, has been widely recognised as a significant cause of morbidities and mortality in neonatal intensive care units (NICUs) worldwide.<sup>1-4</sup> EOS is usually due to vertical transmission occurring *in utero*, during delivery, or after delivery. The mechanisms of *in utero* transmission is due to prolonged rupture of membrane or during labour when organisms in the birth canal enter

through the amniotic membranes causing chorioamnionitis, or the foetus becomes infected by swallowing or inhaling infected amniotic fluid. During birth, a neonate may become infected as it passes through the birth canal. After birth, it may be infected via breaches in its skin or mucus membrane which has been colonised by organisms acquired perinatally.

Given the high morbidities and mortalities associated with EOS, understanding the epidemiology of EOS in each country is of paramount importance to help strategise and

\*Address for correspondence: Nem Yun Boo, Department of Population Medicine, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Jalan Sungai Long, Bandar Sungai Long, Kajang, 43000 Selangor, Malaysia. Email: boony@utar.edu.my.

implement appropriate preventive measures to reduce the burden of this condition. To date, national epidemiology studies of EOS were reported primarily from high-income countries (HICs),<sup>1-8</sup> and none from low- and middle-income countries (LMICs). The objectives of the present study were to determine the incidence, causative pathogens, morbidities, mortality, and risk factors associated with microbiologically culture-positive EOS in NICUs in Malaysia, a middle-income country.

## MATERIALS AND METHODS

This was a retrospective cohort study of neonates born in years 2015-2020 in 44 Malaysian NICUs participating in the Malaysian National Neonatal Registry (MNNR). Data of neonates were collected prospectively in a standardised format by trained health personnel and submitted to the MNNR. The inclusion criteria for neonates in the MNNR were very low birthweight (VLBW, <1500g) or very preterm (VP, <32 weeks) gestation, those with culture-positive sepsis in blood and/or CSF, late preterm/term neonates ( $\geq 35$  weeks) with hypoxic-ischaemic encephalopathy, on respiratory support, death before discharge, or congenital heart diseases (from 2017). All data were anonymised. Data of neonates admitted multiple times were merged before analysis.

### Definitions

Gestation was reported in completed weeks based on antenatal ultrasound findings, or maternal last menstrual period, or the New Ballard scores.<sup>9</sup> Antenatal steroids were any administration of steroids before birth. Outborns were neonates transferred-in to a participating centre. Early continuous positive pressure (eCPAP) therapy was defined as receiving CPAP in delivery rooms shortly after birth. EOS was diagnosed in symptomatic neonates with positive blood culture at  $\leq 72$  hours of life. Necrotising enterocolitis (NEC) was diagnosed based on presence of Bell's stage 2 or 3 changes.<sup>10</sup> Chorioamnionitis was diagnosed by obstetric doctors in the presence of maternal fever ( $\geq 38.0^\circ\text{C}$ ) and any of the following two criteria: maternal tachycardia ( $>100$  beats/minute), foetal tachycardia ( $>160$  beats/minute), leucocytosis ( $15 \times 10^8/\text{L}$ ), raised C-reactive protein, uterine tenderness, foul-smelling liquor.

### Ethics approval

Parental consent was not obtained for this

study as the database was anonymised. Ethical clearance for the study was granted by the Malaysian Ministry of Health and registered under the National Medical Research Registry (NMRR-05-04-168).

### Statistical analysis

The SPSS version 28.0 (IBM) was used for statistical analysis. The incidence of EOS of inborn neonates per 1000 livebirths in the participating hospitals was calculated for each year. We compared maternal and neonatal demographic and clinical data between neonates with and without EOS, and among neonates with EOS due to GBS (GBS EOS), EOS due to non-GBS pathogens (non-GBS EOS) and without EOS of all gestations and birthweights, and in the very low birthweight (<1500g, VLBW) neonates. The Chi Square test was used for analysis of categorical variables and Student t test for continuous variables with normal distributions. Association of predetermined independent factors with EOS due to GBS and with non-GBS EOS were investigated using multiple logistic regression models, respectively. These factors were: maternal age, maternal parity, ethnic groups, maternal diabetes mellitus, chorioamnionitis, antenatal steroids, intrapartum antibiotics, inborn/outborn, birthweight, gestation, intrauterine growth status, gender, modes of delivery, and procedures received shortly after birth (eCPAP, bag-and-mask ventilation, endotracheal intubation, and surfactant therapy). Multicollinearity of independent factors were checked by calculating the variance inflation factors (VIF). Factors with  $\text{VIF} > 4$  were removed from final analysis. P values of  $< 0.05$  were considered statistically significant.

## RESULTS

### Epidemiology

During these six years, there were 1,791,968 livebirths delivered in the participating hospitals. A total of 98355 neonates (both inborns and outborns) admitted to these hospitals met the inclusion criteria of the MNNR. Table 1 shows their demographic characteristics. More than two-thirds of them had birthweight  $\geq 1500\text{g}$  and gestation  $\geq 32$  weeks, and were appropriate for gestational age, Malays and inborns. Of the 98355 neonates, 726 (0.7%) did not have data on EOS status (yes/no). We present here the findings of 97629 (99.3%) neonates with EOS data.

EOS was reported in 991/97629 (1.0%)

**Table 1: Demographic characteristics of all neonates in the Malaysian National Neonatal Database, 2015-2020**

Variables	Number of neonates N=98355 (%)
Mean birthweight, g ( $\pm$ SD)	2316 (884)
Birthweight groups, g	
<1000	6513 (6.6)
1000-1499	14623 (14.9)
1500-2499	32635 (33.2)
$\geq$ 2500	44584 (45.3)
Gestation, weeks	
<28	5275 (5.4)
28 to <32	14781 (15.0)
32 to <37	34114 (34.7)
$\geq$ 37	44185 (44.9)
Intrauterine growth categories	
AGA	68707 (69.9)
SGA	24668 (25.1)
LGA	4980 (5.1)
Ethnic groups	N=98325
Malay	66499 (67.6)
Chinese	7270 (7.4)
Indians	5947 (6.0)
Sabah Indigenous people	5285 (5.4)
Sarawak Indigenous people	4430 (4.5)
Orang Asli	1220 (1.2)
Other Malaysian	547 (0.6)
Foreigners	7127 (7.2)
Gender	
Male	57697 (58.7)
Female	40460 (41.1)
Indeterminate	169 (0.17)
Unknown	29 (0.03)
Place of birth	
Inborn	88299 (89.8)
Outborn	10053 (10.2)
Unknown	3 (0.0)

Note: AGA, appropriate-for-gestational age; SGA, small-for-gestational age; LGA, large-for-gestational age; SD, standard deviation.

neonates. Figure 1 shows the most common pathogen was *Streptococcus agalactiae* or Group B haemolytic streptococcus (GBS) (n=388, 39.2%), followed by *Escherichia coli* (*E. coli*) (n=80, 8.1%), *Klebsiella* spp (n=73, 7.4%), coagulase negative staphylococcus (CONS) (n=73, 7.4%), *Pseudomonas* spp (n=44, 4.4%) and methicillin-sensitive *Staphylococcus aureus*

(n=34, 3.4%). *Listeria monocytogenes* was very uncommon (n=8, 0.8%). In VLBW neonates with EOS (Fig. 2), GBS was the most common (n=76, 22.6%), followed by CONS (n=43, 12.8%), *E. coli* (n=33, 9.8%), *Klebsiella* spp., (n=33, 9.8%), and *pseudomonas* spp. (n=21, 6.2%). In extremely low birthweight (ELBW, <1000g) neonates with EOS, GBS (n=34,




FIG. 1: Causative pathogens isolated in the blood of neonates of all birthweights and gestations with early-onset sepsis in the MNNR in years 2015-2010.

Notes: MSSA, methicillin sensitive *Staphylococcus aureus*; ESBL, extended spectrum Beta lactamase; MNNR, Malaysian National Neonatal Registry.

21.8%) was the most common, followed by CONS (n=19, 12.2%), *E. coli* (n=17, 10.9%), and *Klebsiella* spp. (n=16, 10.3%), In term ( $\geq 37$  weeks gestation) neonates with EOS, GBS was

most common (n=237, 56.4%), followed by *E. coli* (n=30, 7.1%), *Klebsiella* spp. (n=17, 4.0%) and CONS (n=17, 4.0%).

Of the 991 EOS neonates, 853 (86.1%) were




FIG. 2: Causative pathogens isolated in the blood of very low birthweight neonates with early-onset sepsis in the MNNR in years 2015-2010.

Notes: MSSA, methicillin sensitive *Staphylococcus aureus*; ESBL, extended spectrum Beta lactamase; MNNR, Malaysian National Neonatal Registry; VLBW, very low birthweight; EOS, early-onset sepsis.

inborn. The incidence of EOS was 0.48/1000 livebirths (range 0.40-0.57) with an increasing trend in 2018-2020 (Fig. 3). Of the 388 neonates with GBS EOS, 356 (91.8%) were inborn, giving an incidence of 0.20/1000 livebirths (range: 0.15-0.25) which increased gradually over the later three years. The incidence of EOS due to non-GBS pathogens was 0.28/1000 livebirths (range: 0.25-0.34); of these, *E. coli* EOS was 0.04/1000 livebirths (range: 0.02-0.05) and other pathogens was 0.24/1000 livebirths (range: 0.21-0.31).

There were 302/18766 (1.6%) inborn VLBW neonates with EOS, an incidence of 16.1/1000 VLBW livebirths. The five most common pathogens in inborn VLBW neonates were: GBS ( $n=70$ , 3.7/1000 VLBW livebirths), CONS ( $n=41$ , 2.2/1000 VLBS livebirths), *E. coli* ( $n=30$ , 1.6/1000 VLBW livebirths), *Klebsiella* ( $n=29$ , 1.5/1000 VLBW livebirths), and *Pseudomonas* spp. ( $n=16$ , 0.9/1000 VLBW livebirths).

Table 2 compares the neonatal and maternal characteristics between neonates with and without EOS. A significantly higher proportion of EOS neonates were VLBW, very preterm (VPT <32 weeks), appropriate for gestational age, female, singleton, and outborns than those without EOS. Mothers of EOS neonates were significantly younger, with lower gravid and parity status, and had significantly higher proportions of chorioamnionitis, antenatal

steroids and intrapartum antibiotics. There were significantly higher proportions of EOS neonates with respiratory distress syndrome, LOS, patent ductus arteriosus, NEC, and meningitis; received mechanical ventilation (MV), high frequency ventilation (HFV), and inhaled nitric oxide therapy. A significantly lower proportion of them had received CPAP therapy in NICUs than those without EOS. They had significantly higher death rate, and longer duration of hospitalisation. The most common cause of death among the 273 EOS neonates was sepsis. The most common cause of death among 8671 neonates without EOS was major malformations.

#### Neonates with GBS EOS, non-GBS EOS and without EOS

Table 3 shows that mothers of GBS EOS neonates were significantly younger, with lower gravid and parity status; a higher proportion of them were Malays; they had more chorioamnionitis; a lower proportion of them had diabetes mellitus, antenatal steroids, and intrapartum antibiotics. There were significantly more GBS EOS neonates with birthweight  $\geq 2500$ g, gestation  $\geq 37$  weeks, singletons, inborns, spontaneous vertex delivery and meningitis. There were significantly fewer GBS EOS neonates treated with eCPAP, bag-and-mask ventilation, endotracheal intubation, and surfactant therapy. They had lower death rate




FIG. 3: Incidences of culture-positive early onset sepsis in inborn neonates in the Malaysian National Neonatal Registry from 2015 to 2020

Note: EOS, early-onset sepsis; GBS, group B haemolytic streptococci; *E. coli*, *Escherichia coli*.

**Table 2: Comparison of neonatal and maternal characteristics between neonates with and without early-onset sepsis in the Malaysian National Neonatal Registry, 2015-2020**

Variables	Neonates with EOS N=991 (%)	Neonates without EOS N=96638 (%)	P values
<b>Maternal characteristics</b>			
Age, mean±SD	N=982 29.7 (5.7)	N=95959 30.1 (5.9)	0.016
Gravida, median (range)	2 (1-16) N=982	2 (1-19) N=96614	0.044§§
Parity, median (range)	1 (0-15)	1 (0-15) N=96597	0.014§§
No. of abortions, median (range)	0 (0-6)	0 (0-15) N=96616	0.752
Diabetes mellitus	229/957 (23.9)	25233/94416 (26.7)	0.052
Hypertension	118/959 (12.3)	11945/94581 (12.6)	0.763
Eclampsia	32/964 (3.3)	3555/95001 (3.7)	0.491
Anaemia	184/957 (19.2)	17970/94584 (19.0)	0.858
Abruptio placenta	12/965 (1.2)	1835 /95186 (1.9)	0.123
Bleeding placenta previa	15/968 (1.5)	3115/95197 (3.3)	0.003
Cord prolapse	1/966 (0.1)	344/95242 (0.4)	0.274§
Chorioamnionitis	59/962 (6.1)	2466/94962 (2.6)	<0.001
Received antenatal steroid	399/975 (40.9)	35852/95231 (37.6)	0.036
Received intrapartum antibiotics	206/968 (21.3)	16573/95098 (17.4)	0.002
<b>Neonatal characteristics</b>			
Birthweight groups, g			
<1000	156 (15.7)	5949 (6.2)	<0.001
1000-1499	181 (18.3)	14351 (14.9)	
1500-2499	250 (25.2)	32250 (33.4)	
≥2500	404 (40.8)	44088 (45.6)	
Gestation, weeks			
<28	133 (13.4)	4762 (4.9)	<0.001
28 to <32	202 (20.4)	14472 (15.0)	
32 to <37	236 (23.8)	33750 (34.9)	
≥37	420 (42.4)	43654 (45.2)	
Intrauterine growth categories			
AGA	736 (74.3)	67525 (69.9)	0.011
SGA	212 (21.4)	24237 (25.1)	
LGA	43 (4.3)	4876 (5.0)	
Ethnic groups		N=99609	
Malay	688 (69.4)	65429 (67.7)	0.313
Chinese	79 (7.9)	7134 (7.4)	
Indian	64 (6.5)	5853 (6.1)	
Sabah native	47 (4.7)	5125 (5.3)	
Sarawak native	35 (3.5)	4367 (4.5)	
Orang Asli	6 (0.6)	1198 (1.2)	
Other Malaysian	3 (0.3)	531 (0.5)	
Foreigner	69 (7.0)	6972 (7.2)	
Gender			
Male	535 (54.0)	56778/96615 (58.8)	0.010
Female	454 (45.8)	39685/96615 (41.1)	
Indeterminate	2 (0.2)	152/96615 (0.2)	
Multiplicity			
Singleton	943 (95.2)	88943/96615 (92.1)	<0.001
Multiples	48 (4.8)	7672/96615 (7.9)	

Variables	Neonates with EOS N=991 (%)	Neonates without EOS N=96638 (%)	P values
Admitted to NICUs	991 (100)	96475 (99.8)	0.420§
Place of birth			
Inborn	853 (86.1)	86771/96635 (89.8)	<0.001
Outborn	138 (13.9)	9864/96635 (10.2)	
Major congenital malformations	107 (10.8)	10811 (11.2)	0.698
Respiratory distress syndrome	444 (44.8)	34994/96475 (36.3)	<0.001
Meconium aspiration syndrome	56 (5.7)	9066 (9.4)	<0.001
LOS	82 (8.3)	2641 (2.7)	<0.001
PDA	251/906 (27.7)	12644/86905 (14.5)	<0.001
NEC	43 (4.3)	1505/96475 (1.6)	<0.001
Meningitis	128 (12.9)	1023/96475 (1.1)	<0.001
CPAP therapy in NICU	619 (62.5)	69868/96475 (72.4)	<0.001
Mechanical ventilation	726 (73.3)	54321/96475 (56.3)	<0.001
High frequency ventilation	257 (25.9)	8290/96475 (8.6)	<0.001
Inhaled NO therapy	52 (5.2)	1454/96475 (1.5)	<0.001
Death	273 (27.5)	8671 (9.0)	<0.001
Duration of hospitalisation, days			
Median (IQR)			
All neonates	16 (7, 38)	11 (5, 28)	<0.001
Non-survivors	3 (1, 9)	2 (1, 10)	0.049
Survivors	22 (12, 46)	12 (6, 29)	<0.001
Causes of death	N=273	N=8671	
Major malformations	14 (5.1)	2910 (33.6)	<0.001
Sepsis	140 (51.3)	731 (8.4)	
Meningitis	2 (0.7)	19 (0.2)	
Other causes	117 (42.9)	5011 (57.8)	

Note: § Exact test; §§ Mann-Whitney U test; SD, standard deviation; AGA, appropriate for gestation; SGA, small for gestation; LGA, large for gestation. EOS, early-onset sepsis; IQR, interquartile range; CPAP, continuous positive airway pressure; NICU, neonatal intensive care unit; NO, nitric oxide; LOS, late-onset sepsis; PDA, patent ductus arteriosus; NEC, necrotising enterocolitis.

and shorter duration of hospitalisation than non-GBS EOS neonates but had higher death rates and longer hospitalisation than those without EOS. Non-GBS EOS neonates had significantly lower birth weight and gestation, more outborns, received more bag-and-mask ventilation and endotracheal intubation in delivery room, more surfactant therapy, and needing more ventilation support than those with GBS EOS and without EOS. Significantly more neonates with GBS EOS had pneumonia and meningitis than neonates with non-GBS EOS and without EOS ( $p<0.001$ ). Mortality rate was highest among non-GBS EOS neonates.

There were 2525 mothers with chorioamnionitis; 29 of them had neonates with GBS EOS, 30 had neonates with non-GBS EOS, and 2443 had neonates without EOS. Intrapartum antibiotics were given to 72.4% (21/29) of those with GBS EOS neonates, 56.7% (17/30) of those with non-GBS EOS neonates and 73.9% (1305/2443) of those with no-EOS neonates.

#### *EOS in VLBW neonates*

Of the 21136 VLBW neonates in the cohort, EOS status of 20637 (97.6%) neonates were known. Table 4 compares the characteristics and outcome of VLBW neonates with EOS due to GBS and non-GBS pathogens versus those without EOS. There was no significant difference in maternal demographic characteristics and use of antenatal steroids among the three groups. Compared with VLBW neonates without EOS, higher proportion of VLBW neonates with EOS due to GBS and non-GBS pathogens had chorioamnionitis, intrapartum antibiotics, extreme prematurity, vaginal delivery, surfactant therapy, pneumonia, and meningitis. They also had higher mortality rates, longer duration of hospitalisation, higher rates of death due to sepsis.

#### *Risk factors associated with GBS EOS*

Table 5 shows the results of multiple logistic regression analysis of potential risk factors

**Table 3: Comparison of maternal and neonatal characteristics between neonates with and without early-onset sepsis due to GBS and non-GBS pathogens**

Variables	EOS due to GBS N= 388	EOS due to Non-GBS Pathogens N= 603	No EOS N= 96638	P values
<b>Maternal characteristics</b>				
Age in years, mean ( $\pm$ SD)	N=384 28.7 (5.4)	N=598 30.3 (5.8)	N=95959 30.1 (5.9)	<0.001
Gravid status, median (IQR)	2 (1, 3)	2 (1, 4)	N=96614 2 (1, 3)	<0.001
Parity	1 (0, 2)	N=594 1 (0.2)	N=96597 1 (0, 2)	
Ethnic group			N=96609	
Chinese	21 (5.4)	58 (9.6)	7134 (7.4)	<0.001
Malay	299 (77.1)	389 (64.5)	65429 (67.7)	
Indian	28 (7.2)	36 (6.0)	5853 (6.1)	
Other Malaysian	17 (4.4)	74 (12.3)	11221 (11.6)	
Foreigner	23 (5.9)	46 (7.6)	6972 (7.2)	
Diabetes mellitus	80/379 (21.1)	149/578 (25.8)	25233/94416 (26.7)	0.042
Chorioamnionitis	29/381 (7.6)	30/581 (5.2)	2466/94962 (2.6)	<0.001
Antenatal steroids	97/386 (25.1)	302/589 (51.3)	35852/95231 (37.6)	<0.001
Intrapartum antibiotics	66/386 (17.1)	140/582 (24.1)	16573/95098 (17.4)	<0.001
<b>Neonatal characteristics</b>				
Birthweight, g			N=96638	
<1000	34 (8.8)	122 (20.2)	5949 (6.2)	<0.001
1000-1499	42 (10.8)	139 (23.1)	14351 (14.9)	
1500-2499	86 (22.2)	164 (27.2)	32250 (33.4)	
$\geq$ 2500	226 (58.2)	178 (29.5)	44088 (45.6)	
Gestation, weeks			N=96638	
<28	33 (8.5)	100 (16.6)	4762 (4.9)	<0.001
28 to <32	45 (11.6)	157 (26.0)	14472 (15.0)	
32 to <37	73 (18.8)	163 (27.0)	33750 (34.9)	
$\geq$ 37	237 (61.1)	183 (30.3)	43654 (45.2)	
Intrauterine growth				
AGA	287 (74.0)	449 (74.5)	67525 (69.9)	0.007
SGA	77 (19.8)	135 (22.4)	24237 (25.1)	
LGA	24 (6.2)	19 (3.2)	4876 (5.0)	
Female	192 (49.5)	262 (43.4)	39837/96615 (41.2)	0.002
Multiplicity			N=96615	
Singleton	383 (98.7)	560 (92.9)	88943 (92.1)	<0.001
Multiples	5 (1.3)	43 (7.1)	7672 (7.9)	



Variables	EOS due to GBS N= 388	EOS due to Non-GBS Pathogens N= 603	No EOS N= 96638	P values
Place of birth			N=96635	
Inborn	356 (91.8)	497 (82.4)	86771 (89.8)	<0.001
Outborn	332 (8.2)	106 (17.6)	9864 (10.2)	
Mode of delivery			N=96599	
SVD	285 (73.5)	293 (48.6)	38668 (40.0)	<0.001
Breech	6 (1.5)	20 (3.3)	1247 (1.3)	
Forceps	6 (1.5)	4 (0.7)	676 (0.7)	
Vacuum	28 (7.2)	21 (3.5)	5781 (6.0)	
LSCS	63 (16.2)	265 (43.9)	50227 (52.0)	
Early CPAP	103/379 (27.2)	240/591 (40.6)	48503/94713 (51.2)	<0.001
Bag-and-mask ventilation	143/380 (37.6)	284/589 (48.2)	38727/94659 (40.9)	<0.001
Endotracheal intubation	144/380 (27.9)	276/590 (46.8)	35832/94692 (37.8)	<0.001
Surfactant therapy	107 (27.6)	262 (43.4)	22665/96475 (23.5)	<0.001
Mechanical ventilation	279 (71.9)	447 (74.1)	54321/96475 (56.3)	<0.001
High frequency ventilation	90 (23.2)	167 (27.7)	8290/96475 (8.6)	<0.001
Pneumonia	221 (57.0)	193/589 (32.8)	30704/96457 (31.8)	<0.001
Meningitis	65 (16.8)	63 (10.4)	1023/96475 (11.1)	<0.001
Death	83 (21.4)	190 (31.5)	8671/96638 (9.0)	<0.001
Duration of hospitalisation Median (IQR) days	14 (8,22)	22 (7, 47)	11 (5, 28)	<0.001
Duration of hospitalisation of Survivors Median (IQR) days	N=305 15 (10, 25.5)	N=413 29 (16, 60)	N=87967 12 (6, 29)	<0.001
Age of death, median (IQR)days	2 (1,6)	4 (2,11)	2 (1, 10)	<0.001
Causes of death	N=83	N=190	N=8671	
Major malformations	0	14 (7.4)	2910 (33.6)	
Sepsis	59 (71.0)	81 (42.6)	544 (6.3)	
Meningitis	0	2 (1.1)	19 (0.2)	
Other causes	24 (28.9)	93 (48.9)	5198 (59.9)	

Note: EOS, early-onset sepsis; GBS, group B haemolytic streptococci; CPAP, continuous positive airway pressure; IQR, interquartile range; SD, standard deviation; AGA, appropriate for gestational age; SGA, small for gestational age; LGA, large for gestational age; SVD, spontaneous vertex delivery; LSCS, lower segment Caesarean section.

**Table 4: Comparison of maternal and neonatal characteristics between VLBW neonates with and without early-onset sepsis due to GBS and non-GBS pathogens**

Variables	EOS due to GBS N=76	EOS due to Non-GBS Pathogens N=261	No EOS N=20300	P values
<b>Maternal characteristics</b>		N=259	N=20144	
Age in years, mean ( $\pm$ SD)	29.9 (5.9)	30.5 (6.0)	30.2 (6.2)	0.354
Gravid status, median (IQR)	2 (1,3)	2 (1,4)	N=20292 2 (1,3)	0.585
Parity	1 (0,2)	N=258 1 (0,2)	N=20288 1 (0,2)	0.524
Ethnic group (%)		N=261	N=20290	0.131
Chinese	4 (5.3)	27 (10.3)	1811 (8.9)	
Malay	59 (77.6)	153 (58.6)	13017 (64.2)	
Indian	5 (6.6)	18 (6.9)	1290 (6.4)	
Other Malaysian	3 (3.9)	44 (16.9)	2854 (14.1)	
Foreigner	5 (6.6)	19 (7.3)	1318 (6.5)	
Diabetes mellitus (%)	7/75 (9.3)	52/246 (21.1)	4753/19616 (24.2)	0.006
Chorioamnionitis (%)	11/75 (14.7)	19/249 (7.6)	864/19792 (4.4)	<0.001
Antenatal steroids (%)	62 (81.6)	200/254 (78.7)	15434/19992 (77.2)	0.561
Intrapartum antibiotics (%)	35/75 (46.7)	79/251 (31.5)	4695/19951 (23.5)	<0.001
<b>Neonatal characteristics</b>				
Birthweight, g (%)				
<1000	34 (44.7)	122 (46.7)	5949 (29.3)	<0.001
1000-1499	42 (55.3)	139 (53.3)	14351 (70.7)	
Gestation, weeks (%)				
<28	33 (43.4)	100 (38.3)	4714 (23.2)	<0.001
28 to <32	38 (50.0)	132 (50.6)	10238 (50.4)	
32 to <37	5 (6.6)	29 (11.1)	5206 (25.6)	
$\geq$ 37	0	0	142 (0.7)	
Intrauterine growth (%)				
AGA	60 (78.9)	206 (78.9)	13608 (67.0)	<0.001
SGA	9 (11.8)	51 (19.5)	6279 (30.9)	
LGA	7 (9.2)	4 (1.5)	413 (2.0)	
Female (%)	39 (51.3)	126 (48.3)	9847/20289 (48.5)	0.886
Multiplicity (%)			N=20286	
Singleton	72 (94.7)	231 (88.5)	17042 (84.0)	0.006
Multiples	4 (5.3)	30 (11.5)	3244 (16.0)	
Place of birth (%)				
Inborn	70 (92.1)	232 (88.9)	18464 (91.0)	0.481
Outborn	6 (7.9)	29 (11.1)	1836 (9.0)	

Variables	EOS due to GBS N=76	EOS due to Non-GBS Pathogens N=261	No EOS N=20300	P values
Mode of delivery			N=20287	
SVD or Breech	56 (73.7)	127 (48.7)	8239 (40.6)	<0.001
Forceps or Vacuum	0	1 (0.4)	50 (0.2)	
LSCS	20 (26.3)	133 (51.0)	11998 (59.1)	
Early CPAP (%)	29 (38.2)	129/259 (49.8)	10570/19901 (53.1)	0.019
Bag-and-mask ventilation (%)	56 (73.7)	176/258 (68.2)	10718/19892 (53.9)	<0.001
Endotracheal intubation (%)	57 (75.0)	175/258 (67.8)	10553/19896 (53.0)	<0.001
Surfactant therapy (%)	61 (80.3)	200 (76.6)	11943/20190 (59.2)	<0.001
Mechanical ventilation (%)	64 (84.2)	216 (82.8)	13196/20190 (65.4)	<0.001
High frequency ventilation (%)	26 (34.2)	81 (31.0)	3078/20190 (15.2)	<0.001
Pneumonia (%)	29 (38.2)	69 (27.0)	4366/20282 (21.5)	<0.001
Meningitis (%)	9 (11.8)	23 (8.8)	275/20190 (1.4)	<0.001
Death (%)	29 (38.2)	104 (39.8)	3853 (19.0)	<0.001
Duration of hospitalisation Median (IQR) days	42.5 (3.3, 78.3)	42.0 (7.0, 70.0)	42.5 (27.0, 64.0)	0.736
Duration of hospitalisation of Survivors Median (IQR) days	60.0 (44.0, 92.0)	63.0 (44.0, 81.5)	48.0 (35.0, 69.0)	<0.001
Age of death, median (IQR)days	2 (1, 6)	5 (2, 11)	2 (1, 10)	<0.001
Causes of death (%)				
Major malformations	0	2 (1.9)	654 (17.0)	
Sepsis	15 (57.7)	45 (48.9)	336 (8.7)	
Meningitis	0	0	0	
Other causes	14 (48.3)	57 (54.8)	2863 (74.3)	

Note: EOS, early-set sepsis; GBS, group B haemolytic streptococci; CPAP, continuous positive airway pressure; IQR, interquartile range; SD, standard deviation; AGA, appropriate for gestational age; SGA, small for gestational age; LGA, large for gestational age; SVD, spontaneous vertex delivery; LSCS, lower segment Caesarean section;

associated with GBS EOS. There were 90415/97026 (93.2%) neonates with complete set of data for multiple regression analyses; of these 364 were GBS EOS neonates, and 90051 without EOS. After controlling for various potential confounders, seven factors were identified to be significantly associated with increased risk of GBS EOS. These were Indian ethnic group, chorioamnionitis, gestation  $\geq$  37 weeks, female, vaginal delivery, instrumental delivery, and

surfactant therapy. Three factors were associated with significantly lower risk: other Malaysian ethnic group, outborns and eCPAP therapy. The p value for the Hosmer and Lemshow test of the multiple regression analysis was 0.989. The VIF of all independent variables were  $<$  4. The area under receiver operation characteristic (ROC) curve of the regression equation was: 0.793 (95% CI: 0.771, 0.816;  $p <$  0.001).

**Table 5: Multiple logistic regression analysis of potential risk factors associated with early-onset sepsis due to group B haemolytic streptococci in the Malaysian National Neonatal Registry of 2015-2020**

Potential risk factors	Adjusted Odds Ratio (95% CI)	P values
Maternal age, mean±SD	0.981 (0.959, 1.004)	0.101
Maternal parity		
≥3	reference	
1-2	1.117 (0.796, 1.568)	0.522
0	1.369 (0.946, 1.981)	0.095
Ethnic groups		
Chinese	reference	
Malay	1.477 (0.924, 2.362)	0.103
Indian	2.110 (1.172, 3.798)	0.013
Other Malaysians	0.472 (0.241, 0.926)	0.029
Foreigners	0.871 (0.445, 1.706)	0.687
Maternal diabetes mellitus	0.872 (0.671, 1.134)	0.307
Chorioamnionitis	4.119 (2.688, 6.311)	<0.001
Antenatal steroids	0.914 (0.641, 1.304)	0.620
Intrapartum antibiotics	0.872 (0.640, 1.188)	0.385
Outborns	0.464 (0.296, 0.727)	<0.001
Birthweight, g		
<1000	reference	
1000-1499	0.842 (0.443, 1.600)	0.600
1500-2499	0.608 (0.282, 1.310)	0.204
≥2500	0.625 (0.259, 1.511)	0.297
Gestation, week		
<28	reference	
28 to <32	1.078 (0.562, 2.068)	0.821
32 to <37	1.230 (0.551, 2.747)	0.614
≥37	2.902 (1.157, 7.2779)	0.023
Growth status		
AGA	reference	
SGA	0.743 (0.546, 1.011)	0.059
LGA	1.522 (0.984, 2.354)	0.059
Females	1.461 (1.187, 1.799)	<0.001
Mode of delivery		
LSCS	reference	
SVD or breech	5.131 (3.861, 6.818)	<0.001
Instrumental delivery	3.024 (1.922, 4.757)	<0.001
Procedures received shortly after birth		
Early CPAP therapy	0.378 (0.298, 0.479)	<0.001
Bag-and-mask ventilation	0.807 (0.595, 1.095)	0.169
Had ETT intubation	0.900 (0.657, 1.232)	0.510
Surfactant therapy	2.270 (1.648, 3.128)	<0.001

Note: SD, standard deviation; AGA, appropriate for gestational age; SGA, small for gestational age; LGA, large for gestational age; LSCS, lower segment Caesarean section; SVD, spontaneous vertex delivery; CPAP, continuous positive airway pressure; ETT: endotracheal intubation; OR, odds ratio.

*Risk factors associated with non-GBS EOS*

Table 6 shows the results of multiple logistic regression analysis of potential risk factors associated with non-GBS EOS. There were 90582 neonates with complete set of data for analyses: 531 were neonates with non-GBS EOS, and 90051 without EOS. After controlling for various potential confounders, four factors were identified to be significantly associated with increased risk of non-GBS EOS: outborns, extremely low birthweight (ELBW, <1000g), vaginal delivery, and surfactant therapy. eCPAP was identified to be significantly associated with lower risk. The VIF of all independent variables were <4; the Hosmer and Lemshow test  $p=0.095$ . The area under ROC curve was 0.696 (95% CI: 0.674, 0.719;  $p<0.00$ ).

**DISCUSSION**

In this 6-year study of neonates admitted to 62.8% (44/70) of NICUs in Malaysia, the annual incidence of culture-positive EOS showed an increasing trend in the later three years. This increase was mainly due to an increased incidence of GBS, the most common causative pathogen affecting all birthweights and gestational age. Most of the GBS EOS neonates were term/normal birthweight neonates; most of the non-GBS EOS neonates were preterm and/or low birthweight neonates. Compared with neonates without EOS, the duration of hospitalisation, morbidities and mortalities were significantly higher in those with EOS, and mortality was highest among those with non-GBS EOS.

Although the EOS incidence (0.48/1000 livebirths) in our cohort was lower than those reported in HICs ( $\geq 0.7/1000$  livebirths),<sup>5,6,11,12</sup> these population-based studies in HICs were done before 2015 while our findings were based on data of 2015-2020. Recent studies reported from HICs were mainly on VLBW/very preterm neonates. In USA, the incidence of EOS among VLBW was 1.08 (95% CI: 0.95-1.23) cases per 1000 livebirths between 2015-2017,<sup>13</sup> and in Australia and New Zealand it was 0.14/1000 livebirths.<sup>14</sup> In the present study, the incidence of EOS among VLBW neonates in Malaysian NICUs (at 16.1/1000 live births) was very much higher.

Like NICUs of many HICs,<sup>5-7</sup> GBS was the most frequent pathogen isolated in EOS in Malaysia. The incidence of *E. coli* remained very low in neonates of all birthweight and gestation during this period in Malaysia. In recent years, *E. coli* was the most common EOS

pathogen affecting VLBW/preterm neonates with a rising trend in USA,<sup>13</sup> Canada,<sup>15</sup> Germany,<sup>8</sup> and Australia and New Zealand.<sup>14</sup> One possible explanation for these differences between NICUs in HICs and Malaysia could be the different national strategies used to prevent GBS. Currently, all pregnant mothers can be screened antenatally at 35-37 weeks for GBS colonisation (universal screening) or selectively during intrapartum period when presented with fever, or prolonged rupture of amniotic membrane or premature labour (risk-based screening). When GBS is detected by either approach, intrapartum prophylactic antibiotics (IPA) is then administered. Although IPA alone in high risk mothers has resulted in life-saving effects of neonates of maternal GBS colonisation,<sup>16</sup> population studies in HICs showed that universal antenatal screening for maternal GBS colonisation between 35-37 weeks gestation further resulted in significantly lower incidence of GBS EOS than risk-based screening.<sup>17</sup> Since 2002, the Centre for Disease Control and Prevention in USA has recommended universal screening of all pregnant women for rectovaginal GBS colonisation at 35-37 weeks' gestation and administration of IPA to carriers.<sup>18</sup> In Malaysia, we do not have a national policy for universal antenatal screening. We have a national guideline for IPA for "mother with previous baby with invasive GBS disease, preterm labour, GBS carriage in previous pregnancy, prolonged premature rupture of membrane in known GBS carrier, GBS carriage in current pregnancy, and for maternal chorioamnionitis".<sup>19</sup>

Our study concurred with findings elsewhere that chorioamnionitis was a significant risk factor associated with EOS,<sup>20</sup> and that delivery via vaginal route was a significant factor associated with increased risk.<sup>7</sup> Vaginal delivery is a critical point in the transfer of microbes between mother and child,<sup>21</sup> particularly in the presence of chorioamnionitis, leading to bloodstream invasion of mucosa of neonates and resultant EOS. We found that <75% of maternal chorioamnionitis in our cohort received IPA. This could be an important reason accounting for IPA not being identified as a significant factor associated with lower risk of EOS in our cohort unlike those reported by others.<sup>16</sup> Like findings elsewhere, we found antenatal steroids was not a significant risk factor.<sup>22</sup>

The present study did not show any association of decreasing gestational age with an increased risk of EOS.<sup>2,13</sup> Instead, term gestation was a

**Table 6: Multiple logistic regression analysis of potential risk factors associated with early-onset sepsis due to non-group B haemolytic streptococcal pathogens in the Malaysian National Neonatal Registry, 2015-2020**

Potential risk factors	Adjusted OR (95% CI)	P values
Maternal age, mean±SD	1.010 (0.993, 1.028)	0.250
Maternal parity		
0	Reference	
1-2	0.923 (0.754, 1.130)	0.439
≥3	1.014 (0.772, 1.333)	0.918
Ethnic groups		
Chinese	Reference	
Malay	0.887 (0.655, 1.201)	0.440
Indian	0.915 (0.584, 1.434)	0.699
Other Malaysians	0.911 (0.623, 1.331)	0.629
Foreigners	0.878 (0.559, 1.378)	0.571
Maternal diabetes mellitus	1.038 (0.848, 1.271)	0.718
Chorioamnionitis	1.451 (0.972, 2.164)	0.068
Antenatal steroids	1.224 (0.956, 1.568)	0.109
Intrapartum antibiotics	1.231 (0.991, 1.529)	0.061
Outborns	1.837 (1.410, 2.393)	<0.001
Birthweight, g		
≥2500	Reference	
1500-2499	1.076 (0.748, 1.549)	0.692
1000-1499	1.529 (0.943, 2.481)	0.085
<1000	2.333 (1.288, 4.223)	0.005
Gestation, week		
≥37	Reference	
32 to <37	0.902 (0.625, 1.301)	0.581
28 to <32	1.156 (0.698, 1.914)	0.574
<28	1.431 (0.763, 2.685)	0.264
Growth status		
AGA	Reference	
SGA	0.901 (0.700, 1.159)	0.416
LGA	0.761 (0.473, 1.222)	0.258
Females	1.068 (0.897, 1.270)	0.460
Mode of delivery		
LSCS	reference	
SVD or breech	1.397 (1.156, 1.689)	<0.001
Instrumental delivery	1.096 (0.683, 1.757)	0.705
Procedures in DR		
Early CPAP therapy	0.688 (0.573, 0.825)	<0.001
Bag-and-mask ventilation	1.110 (0.878, 1.401)	0.383
Had ETT intubation	0.908 (0.709, 1.163)	0.444
Surfactant therapy	1.506 (1.188, 1.910)	<0.001

Note: SD, standard deviation; AGA, appropriate for gestational age; SGA, small for gestational age; LGA, large for gestational age; LSCS, lower segment Caesarean section; SVD, spontaneous vertex delivery; CPAP, continuous positive airway pressure; ETT: endotracheal intubation; OR, odds ratio.

significant risk factor associated with GBS and ELBW a risk factor associated with non-GBS EOS. Furthermore, neonates of Indian ethnic group were associated with significantly higher risk while 'other Malaysians' were associated with lower risk of GBS. Genetic predisposition and different cultural practices could be the underlying mechanisms. No previous studies have identified female neonates as a risk factor associated with EOS as in this study. We are not able to explain the underlying mechanism of this risk factor.

Outborns was identified as a significant risk factor associated with increased risk of EOS due to non-GBS pathogen but not GBS, suggesting extrauterine acquisition of non-GBS infection during transport could be a possible mechanism. To the best of our knowledge, no previous studies have reported on the role of surfactant therapy and eCPAP as risk factors associated with EOS. In the present study, there were more neonates with EOS receiving resuscitation and surfactant therapy at birth than those without EOS. However, after controlling for various potential confounders, only surfactant therapy was associated with significantly increased risk and eCPAP was associated with lower risk. Compared with either bag-and-mask ventilation and/or endotracheal tube intubation, the process of instillation of surfactant therapy promotes deeper and wider dispersion of pathogens into the lungs either from a contaminated endotracheal tube or surfactant solution, or from the oral-pharyngeal area of a neonate who has inhaled/ingested pathogen during birth. eCPAP therapy is a much less invasive respiratory support and was thus associated with significantly lower risk of EOS. Based on these findings, to reduce EOS in Malaysian NICUs, improving training and monitoring of health care providers in proper sterile techniques of instillation of surfactant in neonates should be considered; and eCPAP therapy should be promoted as a first line respiratory support in neonates who need it.

GBS infection is not uncommon in Malaysia and has been reported even among non-pregnant adults.<sup>23</sup> Given the increasing incidence of GBS EOS in Malaysian NICUs and its associated high morbidities and mortality, and the low use of IPA for chorioamnionitis, several preventive strategies should be considered. These include universal antenatal screening for GBS at 35-37-week gestation, close monitoring of compliance of use of IPA for high-risk pregnancies, provision of adequate facilities and active promotion of

eCPAP in neonates with respiratory distress in delivery rooms, and systematic training and monitoring of all front-line healthcare providers on adherence to strict sterility during surfactant instillation in neonates.

This study has several strengths: a) it was the first national study on epidemiology of EOS in a middle-income country; b) it has a large sample size; c) the data were prospectively collected using a standardised format; d) 62.8% of the NICUs in Malaysia participated in this study and they delivered 68% of all livebirths and 93% of all low birthweight (<2500g) neonates in Malaysia,<sup>24</sup> and e) neonates of all gestation and birthweight with EOS were evaluated.

The major limitation of this study is our inability to determine whether a history of prolonged rupture of membrane or premature rupture of membrane were significant risk factors associated with EOS as these data were not captured in the MNRR database.

In summary, the incidence of EOS showed an increasing trend in Malaysian NICUs. GBS was the most common pathogen. Incidence in VLBW neonates were higher than those in HICs. Several modifiable risk factors associated with EOS have been identified.

*Funding statement:* This work was supported by the Perinatal Society of Malaysia. (Funding number: not applicable).

*Acknowledgement:* We would like to thank the Director General of Ministry of Health of Malaysia for his permission to publish this paper. We would also like to thank the site coordinators of participating hospitals for contribution to the data in this study: Zuraidah Abdul Latif (Ampang Hospital), Zainah Shaikh Hedra (Sultanah Nora Ismail Hospital, Batu Pahat), Anand Mohan A/L Mohana Lal (Bintulu Hospital), Baizura Jamaluddin (Kajang Hospital), Prakash Rao A/L Rama Rao (Keningau Hospital), Farah Inaz Syed Abdullah (Tunku Azizah Hospital), Hasri Hafidz (Tuanku Ampuan Najihah Hospital, Kuala Pilah), Zainab Ishak (Kulim Hospital), Poy-Lee Leow (Melaka Hospital), Chiong Hung Kiew (Miri Hospital), Mehala Devi Baskaran (Pulau Pinang Hospital), Maslina Mohamad (Putrajaya Hospital), Chee Sing Wong (Raja Permaisuri Bainun Hospital, Ipoh), Rozitah Razman (Raja Perempuan Zainab II Hospital, Kota Bharu), Maneet Kaur (Sabah Women and Children's Hospital), Ann Cheng Wong (Sarawak General Hospital), Choo Hau Lim

(Seberang Jaya Hospital), Maizatul Akmar (Serdang Hospital), Seok Chiong Chee (Selayang Hospital), Sheila Gopal Krishnan (Seri Manjung Hospital), Agnes Huei- Hwen Foo (Duchess of Kent Hospital, Sandakan), Intan Nor Chahaya Shukor (Segamat Hospital), Chae Hee Chieng (Sibu Hospital), Chong Meng Choo (Sultan Abdul Halim Hospital, Sungai Petani), Yun Yun Ng (Sultanah Bahiyah Hospital, Alor Setar), Shiau Chuen Diong (Sultan Haji Ahmad Shah Hospital, Temerloh), Hui Ling Chow (Sultanah Aminah Hospital, Johor Bahru), Angeline Seng-Lian Wan (Sultanah Fatimah Specialist Hospital, Muar), Sharifah Huda Engku Alwi (Sultanah Nur Zahirah Hospital, Kuala Terengganu), Kwee Ching See (Sungai Buloh Hospital), Rohani Abdul Jalil (Taiping Hospital), Agnes Suganthi (Teluk Intan Hospital), Mei Ling Lee (Tengku Ampuan Afzan Hospital, Kuantan), Ee Lee Ang (Tengku Ampuan Rahimah Hospital, Klang), Abdul Nasir Mohamed Abdul Kadher (Tuanku Fauziah Hospital, Kangar), Pauline Poh-Ling Choo (Tuanku Ja'afar Hospital, Seremban), Lee Ser Chia (Sultan Ismail Hospital, Johor Bharu), Azanna Ahmad Kamar (University of Malaya Medical Center), Ananda Dharmalingam (Gleneagles Hospital Kuala Lumpur), Ismail Haron (KPJ Puteri Specialist Hospital), Sulockchana Alagan (Kluang Hospital), Noraini Ab Rahman (Kuala Krai Hospital), Nur Rashidah Mohd Zaini (Shah Alam Hospital), Noor Hayati Mohd Sharif (Slim River Hospital).

*Author contributions:* Conceptualization, NYB; data extraction and cleaning, NYB, EBKA, SHN, ELA, SCC; data analysis, NYB; manuscript preparation, NYB; review and editing manuscript, NYB, EBKA, SHN, ELA, SCC.

*Conflict of interest:* The authors declare no conflict of interest.

#### What is already known?

- E. coli has overtaken group B haemolytic streptococci as the most common causative pathogen of neonatal early-onset sepsis in many neonatal intensive care units in high-income countries in recent years.
- Neonatal early-onset sepsis is associated with high morbidities and mortality.
- Chorioamnionitis is a significant risk factor associated with neonatal early-onset sepsis.

#### What this study adds:

- Group B haemolytic streptococci remains the most common causative pathogen of

neonatal early onset-sepsis in all gestational and birthweight groups in the neonatal intensive care units of a middle-income country.

- Surfactant therapy is a significant factor associated with increased risk of neonatal early-onset sepsis.
- Use of early continuous positive airway pressure therapy is associated with significantly lower risk of neonatal early-onset sepsis.

#### REFERENCES

1. Giannoni E, Agyeman PKA, Stocker M, *et al.* Neonatal sepsis of early onset, and hospital-acquired and community-acquired late onset: a prospective population-based cohort study. *J Pediatr* 2018; 201: 106-14.
2. Schrag SJ, Farley MM, Petit S, *et al.* Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. *Pediatrics* 2016; 138: e320162013.
3. Mwaniki MK, Atieno M, Lawn JE, Newton CRJC. Long-term neurodevelopmental outcome after intrauterine and neonatal insults: a systematic review. *Lancet* 2012; 379: 445-52.
4. Klinger G, Levy I, Sirota L, Boyko V, Lerner-Geva L, Reichman B, Israel Neonatal Network. Outcome of early -onset sepsis in a national cohort of very low birth weight infants. *Pediatrics* 2010; 125: e736-40.
5. Cailes B, Kortsalioudaki C, Buttery J, *et al.* on behalf of the neonIN network. Epidemiology of UK neonatal infections: the neonIN infections surveillance network. *Arch Dis Child Fetal Neonatal Ed* 2018; 103: F547-F553.
6. Stoll BJ. Early-onset neonatal sepsis: a continuing problem in need of novel prevention strategies. *Pediatrics* 2016; 138(6).e20163038.
7. Polcwiartek LB, Smith PB, Benjamin DK, *et al.* Early-onset sepsis in term infants admitted to neonatal intensive care units (2011-2016). *J Perinatology* 2021; 41: 157-63.
8. Kostlin-Gille N, Hartel C, Haug C, *et al.* Epidemiology of early and later onset neonatal sepsis in very low birthweight infants. Data from the German neonatal network. *Pediatr Infect Dis J* 2021; 40:255-9.
9. Ballard JL, Khoury JC, Wedig K, *et al.* New Ballard score, expanded to include extremely premature infants. *J Pediatr* 1991; 119: 417-23.
10. Bell MJ, Ternberg JL, Feigin RD, *et al.* Necrotising enterocolitis, therapeutic decisions based upon clinical staging. *Ann Surg* 1978; 187: 1-7.
11. Weston EJ, Pondo T, Lewis MM, *et al.* The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. *Pediatr Infect Dis J* 2011; 30: 937-41.
12. Singh T, Barnes EH, Issacs D, Australian study group for neonatal infection. Early onset neonatal infections in Australia and New Zealand, 2002-2012. *Arch Dis Child Fetal Neonatal Ed* 2019; 104: F248-252.



13. Stoll BJ, Poupolo KM, Hansen NI, *et al.* Early-onset neonatal sepsis 2015-2017, the rise of *Escherichia coli*, and the need for novel prevention strategies. *JAMA Pediatr* 2020; 174: e200593.
14. Duggan HL, Chow SSW, Austin NC, Shah PS, Lui K, Tan K on behalf of the Australian and New Zealand Neonatal Network. Early-onset sepsis in very preterm neonates in Australia and New Zealand, 2007-2018. *Fetal and Neonatal Edition*. Published online first: 15 June 2022. doi:10.1136/archdischild-2021-323243
15. Sgro M, Campbell DM, Mellor KL, Hollamby K, Bodani J, Shah PS for Canadian Neonatal Network investigators. Early-onset neonatal sepsis: organism patterns between 2009-2014. *Paediatrics & Child Health* 2020; 25: 425-31.
16. Poupolo KM, Benitz WE, Zaoutis TE, *et al.* Management of neonates born at  $\geq 35$  0/7 week's gestation with suspected or proven early-onset bacterial sepsis. *Pediatrics* 2018; 142 (6): e20182894.
17. Schrag SJ, Zell ER, Lynfield R, *et al.* A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. *N Engl J Med* 2002; 347: 233-9.
18. Centers for Disease Control and Prevention. Trends in perinatal group B streptococcal disease-United States, 2000-2006. *MMWR Morb Mortal Wkly Rep* 2009; 58: 109-112.
19. Ministry of Health Malaysia. National Antimicrobial Guideline 2019, 3<sup>rd</sup> ed. Available from: <https://www.pharmacy.gov.my/v2/en/documents/national-antimicrobial-guideline-nag-2019-3rd-edition.html>. Accessed on 3 Aug 2022.
20. Poupolo KM, Draper D, Wi S, *et al.* Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. *Pediatrics* 2011; 128: e1155-63.
21. Stewart CJ, Ajami NJ, O'Brien JL, *et al.* Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature* 2018; 562: 583-8.
22. Klinger G, Levy I, Sirota L, Boyko V, Reichman B, Lerner-Geva L, Israel Neonatal Network. Epidemiology and risk factors for early onset sepsis among very-low-birthweight infants. *Am J Obstet Gynaecol* 2009; 201: 38.e1-38. e6.
23. Eskandarian N, Neela V, Ismail Z, *et al.* Group B streptococcal bacteremia in a major teaching hospital in Malaysia: a case series of eighteen patients. *Internat J Infect Dis* 2013; 17: e777-e780.
24. Department of Statistics Malaysia. Vital Statistics Malaysia 2021. ISSN: 0127-466X. <https://www.dosm.gov.my> (accessed on 2 September 2022).